EUR 0.03
(-13.08%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 29.31 Thousand EUR | -96.66% |
2022 | -3.43 Million EUR | 2.36% |
2021 | -3.51 Million EUR | -95.98% |
2020 | -1.79 Million EUR | -4708.59% |
2019 | 38.94 Thousand EUR | 100.42% |
2018 | -9.35 Million EUR | -20417.45% |
2017 | -45.57 Thousand EUR | 99.68% |
2016 | -14.32 Million EUR | -65.19% |
2015 | -8.67 Million EUR | -13.49% |
2014 | -7.64 Million EUR | -1375.85% |
2013 | -517.7 Thousand EUR | -100.7% |
2012 | -257.94 Thousand EUR | 44.45% |
2011 | -464.33 Thousand EUR | 93.73% |
2010 | -7.4 Million EUR | -14.33% |
2009 | -6.47 Million EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -3.11 Million EUR | 0.0% |
2023 Q2 | -3.61 Million EUR | 0.0% |
2023 FY | -6.75 Million EUR | -96.66% |
2023 Q4 | -1.56 Million EUR | 0.0% |
2022 Q2 | -3.55 Million EUR | 0.0% |
2022 Q4 | -1.68 Million EUR | 0.0% |
2022 FY | -3.43 Million EUR | 2.36% |
2021 FY | -3.51 Million EUR | -95.98% |
2021 Q2 | -1.8 Million EUR | 0.0% |
2021 Q4 | -2.73 Million EUR | 0.0% |
2020 Q2 | -1.05 Million EUR | 0.0% |
2020 Q4 | -631.53 Thousand EUR | 0.0% |
2020 FY | -1.79 Million EUR | -4708.59% |
2019 Q2 | 55.9 Thousand EUR | 0.0% |
2019 Q4 | -16.95 Thousand EUR | 0.0% |
2019 FY | 38.94 Thousand EUR | 100.42% |
2018 FY | -9.35 Million EUR | -20417.45% |
2018 Q4 | -4.57 Million EUR | 0.0% |
2018 Q2 | -4.78 Million EUR | 0.0% |
2017 Q2 | -28.05 Thousand EUR | 0.0% |
2017 FY | -45.57 Thousand EUR | 99.68% |
2017 Q4 | -17.52 Thousand EUR | 0.0% |
2016 Q2 | -6.28 Million EUR | 0.0% |
2016 FY | -14.32 Million EUR | -65.19% |
2016 Q4 | -8.03 Million EUR | 0.0% |
2015 FY | -8.67 Million EUR | -13.49% |
2015 Q4 | -4.54 Million EUR | 0.0% |
2015 Q2 | -4.12 Million EUR | 0.0% |
2014 Q2 | -3.61 Million EUR | 0.0% |
2014 Q4 | -4.02 Million EUR | 0.0% |
2014 FY | -7.64 Million EUR | -1375.85% |
2013 Q2 | -2.24 Million EUR | -70.82% |
2013 Q1 | -1.31 Million EUR | -0.0% |
2013 FY | -517.7 Thousand EUR | -100.7% |
2013 Q4 | -2.99 Million EUR | -128.61% |
2013 Q3 | -1.31 Million EUR | 41.46% |
2012 Q1 | -1.4 Million EUR | 0.0% |
2012 Q4 | -1.31 Million EUR | 6.41% |
2012 Q3 | -1.4 Million EUR | 0.0% |
2012 FY | -257.94 Thousand EUR | 44.45% |
2012 Q2 | -1.4 Million EUR | -0.0% |
2011 Q2 | -116.08 Thousand EUR | 0.0% |
2011 Q3 | -116.08 Thousand EUR | 0.0% |
2011 Q4 | -1.4 Million EUR | -1107.73% |
2011 FY | -464.33 Thousand EUR | 93.73% |
2011 Q1 | -116.08 Thousand EUR | 0.0% |
2010 Q2 | -1.85 Million EUR | 0.0% |
2010 Q3 | -1.85 Million EUR | -0.0% |
2010 Q4 | -116.08 Thousand EUR | 93.73% |
2010 Q1 | -1.85 Million EUR | -0.0% |
2010 FY | -7.4 Million EUR | -14.33% |
2009 Q3 | -1.61 Million EUR | 0.0% |
2009 Q1 | -1.61 Million EUR | 0.0% |
2009 FY | -6.47 Million EUR | 0.0% |
2009 Q2 | -1.61 Million EUR | -0.0% |
2009 Q4 | -1.85 Million EUR | -14.33% |
2008 Q4 | -1.61 Million EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ABIONYX Pharma SA | 618 Thousand EUR | 95.257% |
ABIVAX Société Anonyme | 3.91 Million EUR | 99.251% |
Adocia SA | 1.38 Million EUR | 97.883% |
Aelis Farma SA | 12.35 Million EUR | 99.763% |
Biophytis S.A. | -803 Thousand EUR | 103.651% |
Advicenne S.A. | 1.42 Million EUR | 97.944% |
genOway Société anonyme | 20.1 Million EUR | 99.854% |
IntegraGen SA | 5.01 Million EUR | 99.416% |
Medesis Pharma S.A. | -2.66 Million EUR | 101.1% |
NFL Biosciences SA | -56.06 Thousand EUR | 152.287% |
Plant Advanced Technologies SA | 2.15 Million EUR | 98.638% |
Quantum Genomics Société Anonyme | -1.41 Million EUR | 102.065% |
Sensorion SA | 3.78 Million EUR | 99.226% |
Theranexus Société Anonyme | -4.63 Million EUR | 100.632% |
TME Pharma N.V. | -127 Thousand EUR | 123.082% |
Valbiotis SA | 2.66 Million EUR | 98.901% |
TheraVet SA | -530.79 Thousand EUR | 105.523% |
Valerio Therapeutics Société anonyme | 1.26 Million EUR | 97.686% |
DBV Technologies S.A. | 4.15 Million EUR | 99.295% |
Genfit S.A. | 28.22 Million EUR | 99.896% |
GeNeuro SA | -293.8 Thousand EUR | 109.978% |
Innate Pharma S.A. | -4.12 Million EUR | 100.711% |
Inventiva S.A. | 17.5 Million EUR | 99.832% |
MaaT Pharma SA | 1.65 Million EUR | 98.229% |
MedinCell S.A. | 9.28 Million EUR | 99.684% |
Nanobiotix S.A. | 36.2 Million EUR | 99.919% |
OSE Immunotherapeutics SA | 2.22 Million EUR | 98.684% |
Poxel S.A. | 1000.00 EUR | -2831.4% |
GenSight Biologics S.A. | 3 Million EUR | 99.023% |
Transgene SA | -28.4 Million EUR | 100.103% |
Valneva SE | 52.83 Million EUR | 99.945% |